Efficacy of targeted therapy for lung cancer patients included in IMPRESS-Norway, and precision cancer medicine in hard-to-treat rare cancers in the MATRIX-RARE study.
Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido Lopez P, Gregorc V, Haakensen VD, Hiltermann TJN, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Siva S, Solomon B, Qiao Y, Anand S, Chander P, Shcherbakova T, Diaz Perez I, Filippi AR(2026) Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC ESMO Open, 11(2), 106070(in press) DOI 10.1016/j.esmoop.2026.106070, PubMed 41643268
Myhre PL, Helland Å, Myhr KM, Skogås JG, Langø T, Goll R, Vikse J, Fretland SØ(2026) NorTrials drives growth in Norwegian clinical trials Tidsskr Nor Laegeforen, 146(1) DOI 10.4045/tidsskr.25.0685, PubMed 41556676
Van der Pol H, Kringelbach T, Martin Agudo M, Bratseth Stav G, Fagereng GL, Fiocco M, Sørum Falk R, Homer V, Haj Mohammad S, Timmer H, Verlingue L, Helland Å, Rohrberg K, Lassen U, Halford S, Jalkanen K, Juslin T, Krebs MG, Oliveira J, Baltruskeviciene E, Ojamaa K, Taskén K, Gelderblom H(2026) Procedures of data merging in precision cancer medicine: the PRIME-ROSE project Acta Oncol, 65, 1-8 DOI 10.2340/1651-226X.2026.44889, PubMed 41496458
